Portfolio Lab

Abbott Laboratories

  • Stock
  • Ticker ABT
  • ISIN US0028241000
  • NYSE

Health care · Pharmaceuticals · USA

$103.00 −0.84%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Abbott Laboratories since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ABTGlobal equities (VT)

$10,000 grew to $31,255. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −39.6% in 05/2026, measured from the peak in 03/2025. The old peak has not been reached again yet.

1-year return
−14.9%
5-year return p.a.
−2.1%
10-year return p.a.
+12.1%
Volatility p.a.
21.1%
Largest decline
−39.6%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue10,97410,35811,14211,36911,45911,16412,59313,013
Gross profit6,0325,8906,2886,2946,5376,2747,2687,385
Operating income1,9111,6932,0522,0572,2511,3451,6931,358
EBITDA2,2532,0292,4092,4282,6211,7262,0951,773
Net income9,2291,3251,7791,6441,7761,077928920
Earnings per share5.260.761.010.941.020.610.530.53
Balance sheet
Total assets81,41481,44883,99984,18186,713110,429109,215108,247
Liabilities33,51332,38433,17032,91733,94257,72857,45356,624
Equity47,66448,81150,56550,95452,13052,06151,11051,027
Cash7,6166,5326,9517,5118,5226,8035,1044,052
Long-term debt12,62512,73612,93011,5969,89629,63829,60329,451
Cash flow
Operating cash flow2,8681,4172,0472,7873,3151,3152,4881,737
Capital expenditure-720-484-502-496-689-399-497-513
Free cash flow2,1489331,5452,2912,6269161,9911,224

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +52.0%, weakest 2022 at −20.7%. 8 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
4 Nov 2026$0.53
28 Jul 2026$0.53
29 Apr 2026$0.61
20 Feb 2026$1.02
29 Oct 2025$0.94
30 Jul 2025$1.01
30 Apr 2025$0.76
21 Feb 2025$5.26
31 Oct 2024$0.94
31 Jul 2024$0.74
2 May 2024$0.70
16 Feb 2024$0.91

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€162bn
Market cap in trading currency
$178bn
Enterprise value
$205bn
P/E
38.3
P/S
3.70
P/B
3.50
EV/Sales
4.26
EV/EBITDA
25.0
Earnings yield
2.6%
FCF yield
3.8%

Results (last four quarters)

Revenue
$48.2bn
Gross profit
$27.5bn
EBITDA
$8.22bn
Net income
$4.70bn
Earnings per share
$2.69
Revenue per share
$27.85
Revenue growth
+14.5%
Earnings growth
−44.0%

Profitability

Gross margin
56.9%
Operating margin
13.8%
Net margin
9.7%
Return on equity
9.2%
Return on assets
4.3%

Balance sheet and cash flow

Cash
$4.30bn
Cash per share
$2.48
Financial debt
$31.2bn
Debt/equity %
61
Current ratio
1.45
Book value per share
$29.46
Operating cash flow
$8.86bn
Free cash flow
$6.76bn

Dividend

Dividend yield
2.45%
Dividend (12 months)
$2.52
Yield (12 months)
2.45%
Payout ratio
94%
Ex-dividend date
15 Oct 2026

Shares and trading

Shares outstanding
1.73bn
Volume
7.10m
Avg. volume 3 months
8.96m
Relative volume
0.8

Price and technicals

Price
$103.00
1 day
−0.8%
52-week high
$128.90
52-week low
$82.56
Distance to 52-week high
−20.1%
Distance to 52-week low
+24.8%
Distance to 50-day line
−0.9%
Distance to 200-day line
+1.5%
RSI (14)
42
Volatility 1M
32.5%

Performance

1 week
−5.1%
1 month
+0.5%
3 months
−11.7%
6 months
+17.8%
YTD
−17.8%
1 year
−18.4%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ABT performed since 11/2016?

$10,000 grew to $31,255 by 20 Nov 2026, which is +12.1% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ABT?

Volatility was 21.1% per year, measured on monthly returns. The largest decline from a peak was −39.6%, with the low in 05/2026.

How does ABT compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, ABT returned +12.1% at 21.1%. The correlation of monthly returns was 0.46; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Abbott Laboratories (ABT): Return and risk | Portfolio Lab